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Abstract
Two sets of structurally different jatrophanes (1-11 and 13-16), jatrophane 12, and latex extract of 2 Euphorbia species (17 
and 18) were tested for in vitro protective effect against chromosome aberrations in peripheral human lymphocytes using 
the cytokinesis-block micronucleus (CBMN) assay. Jatrophanes 1-6 in minimal doses of 1 µg/mL prominently decreased 
micronuclei (MN) frequency in the range 44.86% to 34.29% and manifested considerable protective effect. From the other 
set of jatrophanes, 13 in the same minimal dose notably decreased MN frequency by 31.05%, while extracts 17 and 18 at a 
concentration of 4 µg/mL remarkably decreased the frequency of MN by 37.94% and 36.12%, respectively. Jatrophanes 12, 
14, and 16 showed moderate protection, while 7-11 and 15 were less active than positive control. The structure-activity 
relationship (SAR) studies of the tested jatrophanes (1-16) indicated the favorable position of benzoate at C-8 or C-9 (3, 
4, and 13) and a preference of isobutanoyloxy group at C-3 (1-3) rather than propanoyloxy at the same position (4-6) for 
pronounced protective effect on human lymphocytes DNA. In a previous SAR study on 11 jatrophanes (1, 3-8, and 13-16), 
the same structural features in 3, 4, and 13 influenced powerful inhibition of P-gp, while growth inhibition of cancer cells was 
more than doubled in 1 (isobutanoyloxy group at C-3) compared to 6 (propanoyloxy at C-3).
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Some degenerative illnesses such as Alzheimer’s and 
Parkinson’s disease manifest in higher level of micronuclei 
(MN) as products of chromosome breakage or loss in periph-
eral blood lymphocytes.1,2 The cytokinesis-block micronu-
cleus (CBMN) assay, based on cytokinesis inhibition by 
cytochalasin B (Cyt-B), has facilitated MN analysis exclu-
sively in binucleate (BN) cells that have completed their first 
in vitro division after treatment with the test agent or follow-
ing culture initiation.3-7 The CBMN assay in peripheral 
blood lymphocytes has been used to detect DNA and chro-
mosome damage as a consequence of an autoimmune dis-
ease,8 chronic kidney disease,9 type 2 diabetes,10 metabolic 
syndrome,11 head and neck cancer,12 and other illnesses, or 
to evaluate the presence and extent of chromosomal damage 
in human populations that are exposed to genotoxic agents.13
Natural phenolic compounds from medicinal herbs and 
dietary plants play an important role in cancer prevention 
and treatment.14 CBMN assays have shown that treatment of 
human lymphocytes with natural phenolic compounds, such 
as flavonoids,15,16 diarylheptanoids,17,18 or seeds extracts 
from grape,19 raspberry, blackberry, and currant,20-22 induced 
decrease in the frequency of micronuclei and manifested 
protective effect on human lymphocytes DNA, compared to 
the action of alkylating agent mitomycin C (MMC) (negative 
control) and/or amifostine WR-2721 (positive control).
Genus Euphorbia (family Euphorbiaceae) is a rich source 
of jatrophanes, macrocyclic diterpenoids with trans-bicy-
clo[10.3.0.]pentadecane structure characterized by a flexible 
12-membered ring. Jatrophanes may perform different bio-
logical activities such as cytotoxic,23 antimicrobial,24 antivi-
ral,25,26 and lipid-lowering activity,27 or may modulate 
overexpression of P-glucoprotein (P-gp) in order to over-
come multidrug resistance to anticancer drugs.28,29 Several 
jatrophanes exhibit microtubule (MT) interacting activity 
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and induce paclitaxel-like microtubules.30,31 Compounds 
that stabilize MT represent potential therapeutic approach 
for the treatment of Alzheimer’s disease and related 
tauopathies.32
In this study 16 jatrophane diterpenoids isolated from 
Euphorbia dendroides33,34 and latex extracts from E. den-
droides and Euphorbia nicaeensis induced decrease in the 
frequency of MN and manifested protective effect on human 
lymphocytes DNA.
Jatrophanes 1-16 and extracts of lyophilized latex of 2 
Euphorbia species (17 and 18) were tested for in vitro pro-
tective effect against chromosome aberrations in peripheral 
human lymphocytes using cytochalasin-B blocked MN 
assay. The cell cultures were treated with amifostine 
WR-2721 (positive control) at a concentration of 1 µg/mL 
and gave a significant (P < 0.01) decrease in the MN fre-
quency of 17.94% compared to control cell cultures. The 
treatment with alkylating agent MMC (negative control) at a 
concentration of 0.2 µg/mL gave a significant (P < 0.01) 
increase in the MN frequency of 36.46% compared to con-
trol cell cultures. After treatment of cell cultures with 1-18 at 
concentrations of 1.0, 2.0, and 4.0 µg/mL, the frequencies 
and distribution of MN in human lymphocytes were scored 
and the results are presented in Table 1.
In the course of a structure-activity relationship (SAR) 
study, jatrophanes were classified into 2 groups. The first 
group (1-11) are penta- or hexaesters with a carbonyl at 
C-14, an endocyclic 11(12)E-double bond, and an exometh-
ylene 6,17-double bond. Jatrophane 12 stands apart as a sin-
gle triester with an additional carbonyl at C-9, otherwise 
with the same structural features as 1-11. The second group 
(13-16) are heptaesters that differ from 1 to 11 by an endocy-
clic-5,6-double bond, instead of an exomethylene 6,17-dou-
ble bond in the latter (Figure 1). In the CBMN assay the 
increased concentration of applied jatrophane (from 1.0 to 
4.0 µg/mL) decreased the level of MN in human lympho-
cytes and consequently afforded better protection.
Jatrophanes 1-3 have shown the prominent protective 
effect in minimal concentration of 1 µg/mL decreasing the 
frequency of MN by 44.86%, 43.53%, and 41.44%, respec-
tively, compared to control human lymphocytes (Table 1). In 
the same concentration jatrophanes 4-6 decreased frequency 
of MN by 36.11%, 34.43%, and 34.29%, respectively. The 
chemical structures of 1-6 are rather uniform and only differ 
in an ester group at C-3 (either OiBu or OPr) and at C-8 
position (OAc, OBz, or ONic), while the rest of the molecu-
lar structure of 1-6 are equal to each other. Higher protection 
of human lymphocyte DNA was observed when isobutanoy-
loxy is at C-3, rather than propanoyloxy at the same position 
(comparison of 1 to 6 and 3 to 4).
Weaker protective effect but still higher than positive con-
trol was observed when the highest dose (4 µg/mL) of 7, 8, 
and 12 was applied, to decrease MN frequency by 23.18%, 
21.09%, and 22.66%, respectively. In the same dose, 
jatrophanes 9-11 that structurally differ from 1 to 8 by 
5-ONic (instead of OAc), 15-OAc (instead of OH), and 
3-OAc (instead of OiBu or OPr), respectively, produced 
lower results than positive control decreasing MN frequency 
by 17.18%, 16.80%, and 8.42%, respectively (Figure 1, 
Table 1). On the other hand much weaker protective effect of 
8 (with isobutanoyloxy at C-3), compared to structurally 
almost identical 5 (propanoyloxy at C-3), cannot be 
explained.
Among the tested jatrophanes of the second group the 
most effective was 13 with benzoyloxy at C-9 that in mini-
mal concentration of 1 µg/mL gave 31.05% decrease in fre-
quency of MN. Jatrophane 14 differing from 13 by a 
nicotinyloxy group at C-9, instead of benzoyloxy at the same 
position in the latter, decreased MN frequency by 20.31%. 
Jatrophane 15 with propanoyloxy at C-3 contrary to acetate 
at C-3 in 14 decreased the frequency of MN by 10.10%. In 
the same concentration 16 with nicotinyloxy at C-8, differing 
from 14 by an acetate at C-8, decreased MN frequency by 
24.93%, respectively.
The tested hexane extracts of lyophilized latex of E. den-
droides (17) and E. nicaeensis (18) exhibited prominent 
effect decreasing the frequency of MN by 37.94% and 
36.12%, respectively, at a concentration of 4 µg/mL when 
compared to control human lymphocytes (Table 1).
Antioxidant potential of heterocyclic compounds using 
CBMN assay has been summarized in a review.35 Polyphenols 
could reduce the incidence of single-strand breaks in dou-
ble-stranded DNA, as well as radical-induced base 
damage.36
MT stabilizing drugs may be utilized in treatment of neu-
rodegenerative diseases to compensate for the loss of tau 
function and to maintain or restore effective axonal trans-
port. Although a growing number of MT stabilizing natural 
products continue to be discovered, only a few selected com-
pounds, such as paclitaxel and epothilone, have been charac-
terized as potential candidates for the treatment of 
neurodegenerative diseases.32
Jatrophanes isolated from Euphorbia semiperfoliata Viv. 
stimulated purified tubulin assembly in vitro. The rearrange-
ment of MT was in contrast to the bundling produced by 
paclitaxel.30 In another study, nontoxic jatrophane 6 that 
showed inhibitory effect on cancer cell was incubated with 
tubulin solution and MT assembly was examined. The IC50 
value for 6 was 29 µM, compared to 0.7 µM for paclitaxel.31 
Despite their structural difference from paclitaxel and other 
MT-interacting agents, the potential of jatrophanes as MT 
stabilizing drugs has not been investigated thoroughly.
As revealed in a previous SAR study on P-gp inhibition of 
11 jatrophanes (1, 3-8, and 13-16) in colorectal carcinoma,34 
3, 4, and 13 happen to be the most powerful inhibitors of 
P-gp. In a SAR study on protective effect against chromo-
some aberrations in peripheral human lymphocytes the larger 
number of jatrophanes (1-16) was examined. The most 
remarkable protection was obtained with jatrophanes 1-6 
and 13 at a concentration of 1 µg/mL. Both SAR studies of 
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Table 1. Incidence of MN, Distribution MN Per Cells, CBPI, and Frequency of MN Measurement in Cell Cultures of Human 
Lymphocytes Treated With Different Concentration of 1-18.
Tested compounds 
and extracts
Conc., µg/
mL
MN/1000 Bn cell % Bn cell with MN MN/Bn Cell CBPI Frequency of MN 
(%)
Control 27.62 ± 0.55 2.29 ± 0.08 1.21 ± 0.03 1.62 ± 0.04 100.00
Amifostine 1.0 22.64 ± 0.78a 1.89 ± 0.10 1.23 ± 0.06 1.65 ± 0.04 82.06
MMC 0.2 37.42 ± 1.78 a, b 3.26 ± 0.15 1.12 ± 0.04 1.76 ± 0.08 136.46
  1 1.0 14.74 ± 1.21 a, b, c 1.18 ± 0.17 1.28 ± 0.09 1.73 ± 0.07 55.14
2.0 14.03 ± 1.26 a, b, c 1.25 ± 0.14 1.12 ± 0.03 1.77 ± 0.07 52.49
4.0 13.69 ± 2.11 a, b, c 1.25 ± 0.13 1.08 ± 0.06 1.58 ± 0.05 51.21
  2 1.0 16.08 ± 0.57 a, b, c 1.42 ± 0.11 1.21 ± 0.07 1.57 ± 0.02 56.47
2.0 15.92 ± 0.61 a, b, c 1.29 ± 0.08 1.19 ± 0.06 1.58 ± 0.03 55.78
4.0 14.74 ± 0.39 a, b, c 1.31 ± 0.08 1.22 ± 0.07 1.63 ± 0.04 51.64
  3 1.0 16.73 ± 1.08 a, b, c 1.41 ± 0.11 1.17 ± 0.07 1.66 ± 0.09 58.56
2.0 16.28 ± 1.31 a, b, c 1.42 ± 0.11 1.18 ± 0.06 1.67 ± 0.08 57.21
4.0 15.64 ± 1.02 a, b, c 1.42 ± 0.09 1.13 ± 0.02 1.67 ± 0.03 54.67
  4 1.0 18.19 ± 0.72 a, b, c 1.48 ± 0.05 1.12 ± 0.05 1.58 ± 0.01 63.89
2.0 17.72 ± 0.59 a, b, c 1.47 ± 0.04 1.18 ± 0.03 1.59 ± 0.01 62.13
4.0 16.78 ± 0.87 a, b, c 1.42 ± 0.04 1.17 ± 0.06 1.61 ± 0.03 58.89
  5 1.0 18.57 ± 0.81 a, b, c 1.59 ± 0.09 1.14 ± 0.09 1.61 ± 0.02 65.57
2.0 18.23 ± 1.10 a, b*, c 1.57 ± 0.09 1.18 ± 0.08 1.59 ± 0.02 63.89
4.0 17.07 ± 1.29 a, b, c 1.52 ± 0.10 1.21 ± 0.09 1.63 ± 0.04 60.02
  6 1.0 17.57 ± 1.12 a, b*, c 1.49 ± 0.12 1.19 ± 0.06 1.70 ± 0.05 65.71
2.0 16.21 ± 1.67 a, b*, c 1.38 ± 0.08 1.17 ± 0.06 2.02 ± 0.03 60.64
4.0 15.56 ± 0.84 a, b, c 1.27 ± 0.11 1.23 ± 0.05 1.61 ± 0.01 58.21
  7 1.0 23.71 ± 0.26 a, c 1.78 ± 0.04 1.31 ± 0.03 1.67 ± 0.09 83.21
2.0 23.33 ± 0.74 a, c 1.79 ± 0.03 1.34 ± 0.05 1.59 ± 0.03 81.78
4.0 21.92 ± 0.65 a, c 1.54 ± 0.08 1.41 ± 0.02 1.67 ± 0.09 76.82
  8 1.0 24.44 ± 0.68 a, c 1.98 ± 0.07 1.31 ± 0.06 1.71 ± 0.08 85.64
2.0 24.01 ± 0.67 a, c 1.92 ± 0.06 1.34 ± 0.06 1.63 ± 0.04 84.25
4.0 22.49 ± 0.39 a, c 1.77 ± 0.09 1.22 ± 0.05 1.67 ± 0.05 78.91
  9 1.0 24.99 ± 0.82a*, c 1.88 ± 0.05 1.28 ± 0.02 1.71 ± 0.02 87.67
2.0 24.51 ± 0.56 a, c 1.86 ± 0.04 1.27 ± 0.03 1.64 ± 0.03 86.04
4.0 23.57 ± 0.62 a, c 1.76 ± 0.14 1.28 ± 0.04 1.76 ± 0.08 82.82
  10 1.0 24.60 ± 0.86c 1.93 ± 0.08 1.28 ± 0.04 1.72 ± 0.04 92.03
2.0 23.75 ± 0.39 a, c 1.86 ± 0.09 1.23 ± 0.05 1.67 ± 0.02 88.85
4.0 22.24 ± 0.63 a, c 1.64 ± 0.13 1.32 ± 0.11 1.66 ± 0.01 83.20
  11 1.0 26.30 ± 1.66c 2.17 ± 0.14 1.21 ± 0.02 1.66 ± 0.06 98.39
2.0 25.25 ± 1.26c 2.09 ± 0.13 1.14 ± 0.04 1.64 ± 0.02 94.46
4.0 24.48 ± 0.81c 1.94 ± 0.10 1.21 ± 0.03 1.67 ± 0.01 91.58
  12 1.0 22.37 ± 0.42 a, c 1.91 ± 0.04 1.13 ± 0.03 1.66 ± 0.05 78.62
2.0 22.04 ± 0.48 a, c 1.89 ± 0.02 1.18 ± 0.03 1.68 ± 0.05 77.18
4.0 20.93 ± 0.89 a, c 1.74 ± 0.06 1.14 ± 0.06 1.59 ± 0.02 77.34
  13 1.0 18.43 ± 0.46 a, b, c 1.56 ± 0.04 1.14 ± 0.05 1.64 ± 0.01 68.95
2.0 17.69 ± 0.83 a, b, c 1.56 ± 0,04 1.08 ± 0.02 1.61 ± 0.02 66.18
4.0 16.40 ± 1.59 a, b*, c 1.34 ± 0.17 1.32 ± 0.06 1.62 ± 0.02 61.35
  14 1.0 21.30 ± 0.95 a, c 1.71 ± 0.12 1.25 ± 0.05 1.71 ± 0.05 79.69
2.0 20.70 ± 0.84 a, c 1.68 ± 0.05 1.23 ± 0.06 1.68 ± 0.06 77.44
4.0 19.37 ± 0.34 a, b*, c 1.66 ± 0.04 1.12 ± 0.04 1.65 ± 0.01 72.46
(Continued)
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the tested jatrophanes pointed out that benzoyloxy at C-8 or 
C-9 (in 3, 4, and 13) is responsible for a prominent degree of 
both P-gp inhibition and DNA protection of human lympho-
cytes. On the other hand jatrophane 1, although a moderate 
P-gp inhibitor, manifested high protective effect in human 
lymphocytes. Furthermore, somewhat higher protective 
effect was observed when isobutanoyloxy is at C-3 (1-3), 
rather than propanoyloxy at the same position (4-6). Previous 
studies demonstrated that 1 with isobutanoyloxy at C-3 
exhibited more than 2 times stronger inhibitory effect on the 
sensitive NCI-H460 cell line and its resistant counterpart 
NCI-H460/R than 6 with propanoyloxy at the same 
position.31
Compounds that stabilize MT may offer therapeutic 
approach for the treatment of Alzheimer’s disease and related 
tauopathies. So far, several jatrophanes exhibited MT inter-
acting activity and induced paclitaxel-like MTs. On the other 
hand detection of DNA and chromosomal damage through 
the elevated level of MN using in vitro CBMN assay in 
peripheral blood lymphocytes may be an indication of sev-
eral diseases, such as Alzheimer’s and Parkinson’s.
Therefore a set of jatrophanes (1-16) and extracts of lyo-
philized latex of 2 Euphorbia species (17 and 18) were sub-
jected to CBMN assay in peripheral blood lymphocytes. 
Jatrophanes 1-6 and 13 (in concentration of 1 µg/mL), and 
extracts 17 and 18 (in concentration of 4 µg/mL) promi-
nently decreased MN frequency and manifested notable pro-
tective effect on human lymphocytes DNA. The potential of 
jatrophanes as MT stabilizing drugs needs further 
investigation.
Experimental
Subjects
Venous blood samples were withdrawn into heparinized ster-
ile vacutainers (Becton Dickinson, Bradford, MA) from 6 
healthy nonsmoking male volunteers who had not been 
exposed to chemicals, drugs, or other substances. A safety 
protocol concerning blood-borne pathogen/biohazard was 
taken. The volunteers consented to use their blood for the 
experiment. From each subject, 2 aliquots of blood, 5 mL 
each were obtained. The study complied with the code of 
ethics of the World Medical Association (Helsinki 
Declaration of 1964, as revised in 2002). The blood samples 
were obtained at the Medical Unit in accordance with current 
Health and Ethical regulations in Serbia, Law on Health Care 
(2005).
Tested compounds 
and extracts
Conc., µg/
mL
MN/1000 Bn cell % Bn cell with MN MN/Bn Cell CBPI Frequency of MN 
(%)
  15 1.0 24.03 ± 0.61a*, c 1.92 ± 0.09 1.20 ± 0.03 1.68 ± 0.02 89.90
2.0 23.43 ± 0.67 a, c 1,83 ± 0.08 1.24 ± 0.05 1.67 ± 0.02 87.65
4.0 21.56 ± 0.71 a, c 1.79 ± 0.09 1.21 ± 0.06 1.70 ± 0.05 80.66
  16 1.0 21.42 ± 0.54 a, c 1.74 ± 0.13 1.29 ± 0.07 1.67 ± 0.08 75.07
2.0 20.97 ± 0.85 a, c 1.78 ± 0.12 1.24 ± 0.08 1.64 ± 0.08 73.73
4.0 19.76 ± 0.93 a, b*, c 1.65 ± 0.06 1.31 ± 0.09 1.60 ± 0.03 69.52
  Euphorbia 
dendroides 
extract 17
1.0 18.89 ± 0.62 a, b, c 1.51 ± 0.06 1.18 ± 0.04 1.67 ± 0.02 66.27
2.0 18.60 ± 0.38 a, b, c 1.58 ± 0.09 1.18 ± 0.05 1.68 ± 0.02 65.33
4.0 17.67 ± 1.71 a, b*, c 1.59 ± 0.12 1.14 ± 0.03 1.70 ± 0.06 62.06
  Euphorbia 
nicaeensis 
extract 18
1.0 19.31 ± 1.07 a, b*, c 1.64 ± 0.09 1.18 ± 0.07 1.56 ± 0.02 67.71
2.0 19.08 ± 1.19 a, b*, c 1.68 ± 0.09 1.21 ± 0.09 1.58 ± 0.02 67.04
4.0 18.19 ± 0.56 a, b, c 1.52 ± 0.08 1.16 ± 0.06 1.60 ± 0.02 63.88
Abbreviations: CBPI, cytokinesis-block proliferation index; MMC, mitomycin C.
MN/Bn cells: incidence of micronuclei in binucleated cells.
% Bn cells with MN: binucleated cells with micronuclei.
MN/1000 Bn cells: incidence of micronuclei in 1000 binucleated cells (examined for each concentration).
Frequency of MN: incidence of MN present like % from control groups in cell cultures of human lymphocytes treated with different concentration of 
jatrophanes or plant extracts.
The statistical significance of difference between the data pairs was evaluated by one-way analysis of variance followed by the Tukey test. Statistical 
significance at P < 0.01.
aCompared with control groups, statistically significant at P < 0.01.
a*Compared with control groups, statistically significant at P < 0.05.
bCompared with amifostine WR 2721, statistically significant at P < 0.01.
b*Compared with amifostine WR 2721, statistically significant at P < 0.05.
cCompared with MMC, statistically significant at P < 0.01.
c*Compared with MMC, statistically significant difference P < 0.05.
Table 1. Continued
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Cytokinesis-Block Micronucleus Assay
Jatrophanes 1-16 were isolated and purified as described.33,34 
Lyophilized latex (200 mg) of E. dendroides and E. nicaeen-
sis were extracted with petroleum ether (30 mL, 3 times) to 
obtain extracts of lyophilized latex 17 (170 mg) and 18 (155 
mg). The culture lymphocytes were treated with 3 concentra-
tions (1, 2, and 4 µg/mL) of jatrophanes 1-16 and latex 
extracts 17 and 18. One cell culture served as the control and, 
to this, jatrophane or lyophilized latex extract was not added. 
Amifostine WR-2721 (Marligen-Biosciences, USA) (1 µg/
mL) was used as a positive control and MMC (0.2 µg/mL, in 
phosphate buffer) as a negative control. All cultures were 
incubated in a thermostat at 37°C. Treatment with 1-18 lasted 
19 hours, when after all cultures were rinsed with pure 
medium, transferred into 5 mL fresh RPMI 1640 medium 
(RPMI 1640 Medium +GlutaMAX + 25 mM HEPES; 
Invitrogen-Gibco-BRL, Vienna, Austria) and incubated for 
additional 72 hours. The incidence of spontaneously 
occurring MN in control samples was scored. The further 
treatment of all cultures was previously described.20
Statistical Analysis
The statistical analysis was performed using Origin software 
package version 7.0. The statistical significance of difference 
between the data pairs was evaluated by one-way analysis of 
variance followed by the Tukey test. Statistical difference 
was considered significant at P < 0.01. The index calculating 
is presented as the percent of change comparing different 
groups.
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Figure 1. Structures of the tested jatrophanes isolated from Euphorbia dendroides and Euphorbia nicaeensis.
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